摘要
目的探讨塞来昔布对非小细胞肺癌(NSCLC)放疗增敏作用的影响。方法回顾性分析2012年5月—2013年10月收治的NSCLC患者90例,按治疗方法分为研究组44例和对照组46例,对照组予以同步放化疗方案,研究组在对照组基础上给予塞来昔布口服,观察2组临床疗效、不良反应发生情况,比较治疗前后KPS评分及治疗后2年内生存情况。结果研究组治疗总有效率及1年、2年生存率均高于对照组,差异有统计学意义(P<0.05)。2组严重不良反应发生率比较差异无统计学意义(P>0.05)。治疗6个周期后,2组KPS评分较治疗前提高,且研究组高于对照组,差异有统计学意义(P<0.05)。结论同步放化疗同时联合塞来昔布口服能有效增加NSCLC患者放疗敏感性,可提高临床疗效、延长患者生存时间。
Objective To investigate the effect of Celecoxib on sensitization of radiotherapy for non-small cell lung cancer （NSCLC）. Methods Clinical data of 90 patients with NSCLC treated during May 2012 and October 2013 was retrospectively analyzed, and the patients were divided into study group （ n = 44） and control group （ n = 46）. Con- trol group received concurrent radiochemotherapy, and study group was added with Celecoxib orally on the basis of con- current radioehemotherapy. In two groups, the clinical curative and incidence rate of adverse reactions were observed; Karnofsky performance status （kps） scores before and after treatment, and survival rate within 2 years after treatment were compared. Results Values of total effective rate, 1-year and 2-years survival rates in study group were significantly higher than those in control group （ P 〈 0.05）. There was no significant difference in incidence rate of adverse reactions between the two groups （P 〉 0. 05 ）. After six cycles of treatment, kps scores were significantly higher than those before treatment in two groups, and the score in study group was higher than that in control group （P 〈 0. 05）. Conclusion Concurrent radiochemotherapy combined with oral Celecoxib can effectively increase the radiosensitivity, and it can also improve clinical curative effect and prolong survival time of patients with NSCLC.
作者
李丽萍
余志高
李小菊
鲁文静
LI Li-ping YU Zhi-gao LI Xiao-ju LU Wen-jing(Department of Oncoiogy, the First Peopleg Hospital of Xiantao City, Xiantao, Hubei 433000, Chin)
出处
《解放军医药杂志》
CAS
2017年第1期40-42,46,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
湖北省科技厅重点扶持计划(2014092)
关键词
癌
非小细胞肺
塞来昔布
放化疗
辐射增敏药
Carcinoma, non-small-cell lung
Celecoxlb
Chemoradiotherapy
Radiatlon-sensitizing agents
